Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jeff O. Fossum
Jeff O. Fossum is Senior Vice President, Systems, for Ashton Technology.
Mr. Fossum leads all system engineering and integration activities for internal, external, and joint development. He also supports marketing, training, and operations in connection with new products and services.
Mr. Fossum leads the design, implementation, integration, testing, and operation of Ashton’s intelligent matching systems, including the eVWAP™ trading system which was completed in April 1997. He led the successful development of the Universal Trading System, a highly secure, fault tolerant, modular, and expandable client-sever infrastructure, which hosts eVWAP and future intelligent matching products. Mr. Fossum and his team designed and implemented a highly secure wide area network (WAN) that allows authenticated users to submit orders within seven seconds from anywhere in the world and is expandable to Internet/Extranet access. Mr. Fossum implemented the central database including the matching algorithms. In addition, he established system interfaces to the Philadelphia Stock Exchange (PHLX) PACE system, the national market data feeds, and PHLX settlement and clearing systems. Mr. Fossum has worked on requirements and designs for future products, briefed and demonstrated eVWAP to a variety of audiences, and acts as a liaison to the PHLX on technical matters.
Prior to joining Ashton, Mr. Fossum was a Senior Associate at Booz·Allen and Hamilton Inc. During his nine years at Booz· Allen, he helped establish and ultimately led the 50 person Advanced Computational Technologies Practice. Mr. Fossum and his staff were responsible for marketing, business development, and successful performance on over $10 million of federal and commercial contract work involving complex system design and implementation and the application of advanced computational technologies. For the military and intelligence community, he designed and developed advanced signal and speech processing and recognition systems. Mr. Fossum led the development of a commercial neural network development system with Motorola, Inc. This client-server system provided automatic parallel code generation from a graphical specification for an arbitrary number of 64-processor computer chips yielding real time execution for neural network applications. He also led the development of three large multimedia systems for federal law enforcement agencies and the military. These advanced systems integrated image, video, speech, fingerprint, and text capture into secure, distributed database environments that provided search and retrieval using advanced pattern recognition techniques for text, fingerprint, speech, and image data. Two of these systems received national recognition from their respective federal agency clients. In 1991, Mr. Fossum was part of a team that won the highly coveted Booz·Allen Professional Excellence award.
Prior to joining Booz·Allen, Mr. Fossum was an artificial intelligence (AI) software engineer with Loral Advanced Projects in Reston, VA, where he developed neural network-based radar identification systems. Prior to Loral, Mr. Fossum was an AI software engineer with Contel Spacecom in Gaithersburg, MD where he developed expert system-based, satellite control software for NASA’s Tracking and Data Relay Satellite System. Prior to Spacecom, Mr. Fossum was a computer scientist with NASA’s Goddard Space Flight Center in Greenbelt, MD where he developed ground support and flight software for sounding rockets and space shuttle-based satellite payloads.
Mr. Fossum is a recognized expert in the field of neural networks and has been a lecturer to government, industry, and academia, including the Artificial Intelligence Institute in Ulm, Germany. He has authored or co-authored several scientific papers and publications. He received a Bachelor’s degree in Computer Science from North Dakota State University and a Master’s degree in Computer Science from the George Washington University in Washington, DC.
http://www.ashtontechgroup.com/aleaders/fossum.html
Fredric W. Rittereiser
Fredric Rittereiser serves as Chairman of the Board and Chief Executive Officer of Ashton. He is a cofounder of Ashton and its Universal Trading Technologies Corporation (UTTC™), Gomez Advisors, Inc., and electronic Market Center (eMC) affiliates. Mr. Rittereiser has led the product development efforts of UTTC and is directly responsible for the intelligent matching systems concept.
Mr. Rittereiser has been responsible for Ashton’s strategic initiatives concerning the Chinese market, E.Com and the conceptualization of the electronic Market Center (eMC™). In addition to his strategic responsibilities, Mr. Rittereiser has led all of Ashton’s financing, marketing and executive recruiting efforts.
Prior to the founding of Ashton, Mr. Rittereiser served as a special consultant to Booz•Allen and Hamilton Inc.’s technology practice where he focused on the financial services industry’s use of encrypted online transaction systems.
Mr. Rittereiser has over 30 years of experience in the financial services industry, having served as the President of Sherwood Group, Troster Singer, and Instinet. During his career as a senior executive on Wall Street, Mr. Rittereiser raised capital for over 20 companies and served on the Board of numerous private and public companies. From 1972 through 1980, Mr. Rittereiser was active on numerous NASD committees including National Market System, Ethics, Options, Arbitration and Corporate Finance.
Mr. Rittereiser is considered a pioneer in the field of electronic trading systems for the financial markets. While President of Instinet, Mr. Rittereiser was responsible for Instinet’s two most successful products – a dealer trading system for NASDAQ securities and the Instinet Crossing Network. In addition, Mr. Rittereiser introduced Instinet to a number of domestic and international exchanges. Mr. Rittereiser was responsible for Instinet’s strategic acquisition by Reuters.
http://www.ashtontechgroup.com/aleaders/ritterei.html
William W. Uchimoto
William W. Uchimoto is Executive Vice President, General Counsel, and Director of Ashton and UTTC. He is President of UTTC’s NextExchange.
Prior to joining Ashton in 1997, Mr. Uchimoto was Senior Vice President and General Counsel of the Philadelphia Stock Exchange, Inc. (PHLX), and its subsidiaries from 1986 to 1997, serving as the PHLX’s representative to joint industry associations relating to National Market System (NMS) facilities such as the Consolidated Tape Association, the Intermarket Trading System (ITS), and the Options Price Reporting Authority.
As an executive officer of the PHLX, Mr. Uchimoto represented the Exchange and its clearing agency subsidiaries before all regulatory bodies, including the Securities and Exchange Commission (SEC), Commodity Futures Trading Commission and Board of Governors of the Federal Reserve System. Mr. Uchimoto is recognized as an expert on NMS issues and penned virtually all of the PHLX's comment positions on market structure and regulatory issues. He negotiated the PHLX’s participation in the over-the-counter/unlisted trading privileges (OTC/UTP) Plan and drafted the exchange’s positions respecting options market linkages, and directed all legal/regulatory work on new trading systems and listed products.
From 1981 to 1986, Mr. Uchimoto was an attorney in the SEC's Division of Market Regulation. While at the SEC, Mr. Uchimoto worked on market structure issues such as developing the Congressionally mandated NMS, and drafted the OTC/UTP release (permitting exchanges to trade NASDAQ securities) and permanent approval order for the National Securities Trading System, which was the first fully electronic exchange.
At the SEC, Mr. Uchimoto also drafted the permanent approval order for the ITS, and approval orders for the New York Stock Exchange’s SuperDot System and the National Association of Securities Dealers’ (NASD) Small Order Execution System. He also provided critical input and drafted significant releases on the terms and conditions upon which the Institutional Networks Corporation could compete with the NASD in distributing full NASDAQ market maker quotations to professionals and the public.
Mr. Uchimoto is a frequent conference speaker on best execution and market regulation topics. He also is a lecturer to the International Law Institute in Washington, DC. He periodically has been on the adjunct faculty of several Philadelphia area law schools, teaching courses in Securities Regulation.
Mr. Uchimoto received his law degree from the University of California, Hastings College of Law (1981) and his Bachelor’s degree in Economics from the University of California at Davis (1978). Mr. Uchimoto is a member of the California Bar and the U.S. Court of Appeals for the Ninth Circuit.
http://www.ashtontechgroup.com/aleaders/uchimoto.html
Fred S. Weingard
Fred Weingard is currently a director of Ashton and UTTC. He also serves as Executive Vice President and Chief Technology Officer of Ashton and leads the design and implementation of their strategic systems.
Mr. Weingard provides management and technology leadership for development projects, designs financial analytical tools, and performs due diligence for technology of strategic plans, partnerships and acquisitions. Mr. Weingard briefs and demonstrates the products to a diverse spectrum of audiences, supporting marketing, selling, training, and operations with respect to the implementation of new products, services and systems.
Mr. Weingard’s recruiting, design, implementation and testing led to the final development of the eVWAP™ trading system. He led efforts that produced a state-of-the-art security infrastructure for eVWAP and for future products including: advanced encryption, authentication, multilevel firewalls, B-2 & C-2 level trusted subsystems, and proprietary access control mechanisms.
Prior to joining Ashton, Mr. Weingard was a Principal at Booz•Allen and Hamilton Inc. During his eleven years at Booz•Allen, he founded and directed the Advanced Computational Technologies Practice (ACTP) that grew to over 50 technology and systems personnel in three locations. Mr. Weingard and his staff were responsible for marketing, selling, and the successful performance of over $45 million of federal and commercial contract work involving complex system design and implementation, and application of advanced computational technologies. Application domains included: military; intelligence community; financial; marketing; law enforcement; biometrics; health care/medical; and manufacturing. Application areas included: pattern recognition; risk assessment; tracking and prediction; information and concept representation; filtering, fusion and analysis; modeling and simulation; autonomous decision systems; multimedia and intelligent databases; parallel and distributed processing systems; information compression and security; and speech, signal, image, text processing and recognition. Technology areas included: artificial intelligence (AI); neural networks; advanced statistics and mathematical modeling; parallel processing; and client-server, middleware and database technologies.
In 1991, Mr. Weingard and several of his staff won the highly coveted Booz•Allen Professional Excellence award. Just prior to leaving Booz•Allen, Mr. Weingard headed a team to recruit, challenge, and retain world-class technology and systems.
Prior to joining Booz•Allen, Mr. Weingard spent five years as a senior intelligence analyst for the Defense Intelligence Agency in Washington, DC. Prior to DIA, Mr. Weingard spent five years as a lead Nuclear Engineer for an architectural engineering firm in New Jersey.
A nationally recognized expert in the field of neural networks, Mr. Weingard has been an invited panelist and lecturer for government, industry, academia, and professional societies. He has authored or co-authored over 12 scientific papers and publications and is a National Science Foundation national mathematics award winner. For over 16 years he has held US government clearances above top-secret and holds Professional Engineering licenses in mechanical engineering from New York and Washington States. Mr. Weingard is the sole inventor of two US patents in the field of neural networks and is accredited with inventing five Booz•Allen proprietary technologies/products.
Mr. Weingard received his Bachelor’s degree in Physics and his Master’s degree in Nuclear Engineering from Cornell University in New York, and a Master’s degree in Computer Science from the George Washington University in Washington, DC.
http://www.ashtontechgroup.com/aleaders/weingard.html
The real ASTN resumes on their website.
http://www.ashtontechgroup.com/alead.html
"Don't be so lazy."
Isn't that a personal attack?
IMO it's ridiculous to say that everyone who posts a copy of a PR is responsible for proving the statements in that PR. I did not compose the PR or any of the statements within, I'm just quoting it.
You are not an attorney, therefore you do not have the expertise to make judgements about legal issues. Are you are being sued for something copied from a PR? It's not the same is it?... apples and oranges.
Sara
"...You're known by the company you keep..."
Exactly!
Sara : )
"Yes, it's from the PR
but it's not correct. I corrected you. Go email tony and ask him yourself."
Geez, you expect me to believe that? Well... you know I don't believe anything you say... and I sure don't have reason to believe he is anymore credible... particularly since you seem to defend him.
If the PR is incorrect, then we'll have to watch the outcome of the legal proceedings... unless you can provide a credible source to prove the PR false.
Quoting from a PR is perfectly reasonable IMO.
Sara
"recently paroled felon" is a quote right out the PR which I posted a link to.
Sara
SulphCo, Inc. Sues to Protect Shareholders
RENO, Nev., June 29 /PRNewswire/ -- SulphCo, Inc. (OTC Bulletin Board: SLPH - news) today announced that it has filed a lawsuit to protect shareholders from irresponsible reporting and corresponding stock manipulation by Defendant and recently paroled felon Amir Ibrahim Elgindy, also known as Anthony Elgindy and Tony Elgindy, doing business as Pacific Equity Investigations and Inside Truth.com.
http://biz.yahoo.com/prnews/010629/laf007.html
SulphCo, Inc. Sues to Protect Shareholders
RENO, Nev., June 29 /PRNewswire/ -- SulphCo, Inc. (OTC Bulletin Board: SLPH - news) today announced that it has filed a lawsuit to protect shareholders from irresponsible reporting and corresponding stock manipulation by Defendant and recently paroled felon Amir Ibrahim Elgindy, also known as Anthony Elgindy and Tony Elgindy, doing business as Pacific Equity Investigations and Inside Truth.com.
http://biz.yahoo.com/prnews/010629/laf007.html
Great post Arch! eom
mmayr,
"HRCT could have done a better job researching someone that was experience at handling message boards."
Totally agree with that : )
Take care,
Sara
I get it now! Thanks! eom
EZ - re LINK
I've been into LINK for sometime. I think it's a real solid company in an industry that is right for the times. Their PE is around 28.
Take a special look at their website and their featured product... a remote keyboard. The company I work for just bought one of those and I personally would love to have one.
website
http://www.interlinkelec.com
Business Overview (from CS)
LINK designs, manufactures and sells input devices for computers and other electronic products based on the Company's proprietary technologies, including Force Sensor Resistor technology. For the 3 months ended 3/31/01, revenues decreased 4% to $7.4M. Net income increased 3% to $733K. Revenues reflect lower sales to customer in the e-transaction and broadband home entertainment market. Earnings benefitted from income tax benefits.
Growth Rates
1 Year 3 Year 5 Year
Revenue Growth Rate Annualized (%) 20.51 20.93 25.82
EPS Growth Rate Annualized (%) 32.23 311.64 67.76
I'm holding this for the long haul...
Sara
mmayr,
It's all a matter of frame of reference. I have a friend who grew up in Brooklyn and this type of thing would not phase him one bit. But many of us don't encounter those types of "disgusting morons" in our everyday life and certainly don't expect that when we first come onto the the stock boards. Although I would agree with you that in order to survive boards like RB, you have to learn to not take things personally... to understand someone is just getting their jollies trying to make you angry. But, IMO, it's not sentimental to wish that people had more built in character, intergrity and civility and that these places couldn't all be more like IHub. For instance, I am trying to get my kids interested in investing... but there is no way I would allow them on these boards to be exposed to the kind of things you see here... and that's just a shame.
Take care,
Sara
OT: EZ - thanks : ) eom
eVWAP 186,000 X 2
By: stosh_5 $$$
Reply To: None Friday, 29 Jun 2001 at 9:41 AM EDT
Post # of 20198
186,000 x 2 confirmed
http://ragingbull.lycos.com/mboard/boards.cgi?board=ASTN&read=20193
Thanks for the graph and analysis. My mistake was having the stochastic at the default of 15-5-5... which I have no idea what it means. I checked ClearStation, as that's where I first starting looking at stochastics, and it looks much more like your version. Could you explain what the settings mean? Should I always use 5-3-3 or does it vary on stock or circumstance?
Sara : )
You think maybe you might just be a bit biased? With ASTN suing you, I doubt you can be objective. IMO nobody's expecting anything great in the report, but it's obvious you are just dying to look at it and try and find every little negative thing.
Funny thing about the eVWAP graph... it shows up for me.
Sara
OT: EZ...
I understand her shock at the way she was treated as I still remember my own shock about a year and a few months ago when I first started participating on stock chat boards. It's really too bad people feel so free to act so badly because they are anonymous.
I'd love to hear if she actually files suit against those posters... sometimes I think that's the only thing that will stop some of these people... a few lawsuits won against them.
Sara
Muel & XXray,
I was burned a couple times when holding stocks that then did reverse splits, but I've noticed that sometimes there's an opportunity right after the split for a little jump. What do you guys think?
Sara : )
TEVA looking bullish today...
http://www.askresearch.com/cgi-bin/chart?symbol=TEVA&country=USA&size=640x480&months=3+m...
Sara : )
re: reverse splits...
Yikes, is there an increase in reverse splits lately or is it just that you are pointing them all out to us?
Sara : )
Reid,
I think I'm experiencing first hand exactly what you are saying... looking forward to any further comments you have. Thanks.
Sara : )
Chart of eVWAP volumes:
Yipee!
Sara : )
Saw lots of FTWB spam over on Yahoo...
You guys are putting out alot of good info here... keep up the good work!
Sara : )
More on today's record... monthly record!
By: stosh_5 $$$
Reply To: None Thursday, 28 Jun 2001 at 10:23 AM EDT
Post # of 20154
I just talked to Art Bacci.
This is twice in less than an hour that I was reduced to babbling - I simply had to confirm that we didn't have another screw up like last Thursday so I called Ashton. When the receptionist asked me to hold I figured I'd get some flunky, so when Bacci came on the line I was a bit surprised to say the least. Anyway, the 4,075,500 x 2 is correct. There were actually 7,000,000 shares in the system, but all could not be matched.
After he confirmed, I said that was about the best news I'd heard in a long, long time. He said something like, "I understand you folks have been waiting a long time, but we've been telling you we're very close."
This is a good day folks. Volume for the month is 13,742,000 x 2. Certainly not break-even, but it's going to help the cash situation a bit.
Have a great day everyone.
Stosh
http://ragingbull.lycos.com/mboard/boards.cgi?board=ASTN&read=20152
correction 4,075,500 X 2 - Still WOW!
By: stosh_5 $$$
Reply To: 20141 by Shulman_no_baka $$$ Thursday, 28 Jun 2001 at 9:50 AM EDT
Post # of 20151
I'm not kidding. I just called them again because I wanted to double-check. Poobah posted 4,750,500 x 2 on Yahoo, so I wanted to be certain I had the right number. I do, Poo's got a zero in the wrong place, but 4,075,500 is still just dandy.
Stosh
http://ragingbull.lycos.com/mboard/boards.cgi?board=ASTN&read=20142
4,750,500x2.......WOW
by: the_grand_poobah2000
Long-Term Sentiment: Strong Buy 06/28/01 09:44 am
Msg: 122307 of 122331
<EOM>
http://messages.yahoo.com/bbs?.mm=FN&action=m&board=4687979&tid=astn&sid=4687979&...
Question about a chart...
I'm looking at the MFNX chart and see a nice oversold stochastic, a fairly nice little up trend for a couple days, but today it ended down a bit. Volume seems good. In general I'd like your comments. Also, I've read the description of OnBalanceVolume, but am not sure if the down trend is good or bad in this case. tia
http://www.askresearch.com/cgi-bin/chart?symbol=MFNX&country=USA&size=640x480&months=3+m...
Sara
Geez... music coming from this site... guess I should expect strange things from Area 51... lol
Sara
thanks EZ : ) eom
LINK up today on bad news??? strange. eom
"Go ahead and make it happen anyway."
Great post Muel.
Sara : )
Genta's CEO Highlights Clinical Progress of Genasense(TM) and Intellectual Property Strength at Major Industry Forum
Wednesday June 27, 9:44 am Eastern Time
Press Release
SOURCE: Genta Incorporated
Genta's CEO Highlights Clinical Progress of Genasense(TM) and Intellectual Property Strength at Major Industry Forum
BERKELEY HEIGHTS, N.J., June 27 /PRNewswire/ -- Genta Incorporated (Nasdaq: GNTA - news) announced that its Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr., presented an overview of the Genasense(TM) clinical program and intellectual property status on Tuesday at the BIO 2001 Investor & Partnering Forum in San Diego, CA. The presentation also highlighted new clinical data that was presented on Sunday at the annual meeting of the European Hematology Association (EHA) in Frankfurt, Germany.
At the EHA meeting the Company presented preliminary evidence of single-agent activity from new studies in chronic lymphocytic leukemia (CLL). Several patients experienced marked reductions in circulating leukemia cells after treatment with Genasense(TM) alone. This result reaffirmed single-agent responses previously reported in patients with lymphoma who had also responded with improvements in circulating lymphoma cells. The data followed several lectures that were presented at the State-of-the-Science meeting sponsored by the National Cancer Institute two weeks ago, which showed that Bcl-2 is a critical factor for CLL cell survival that can be knocked out by Genasense(TM).
Dr. Warrell commented: ``While this CLL trial was primarily designed to support the pharmacokinetic and biokinetic portions of next year's planned New Drug Application (NDA), early clinical results have been quite positive. Obviously, this clinical activity as a single agent is very encouraging for our ongoing Phase 3 trial in CLL that uses Genasense(TM) in combination with other active drugs.'' In other comments, Dr. Warrell noted:
``Genta is alone among companies with antisense technology in having established the scientific ''proof-of principle`` for antisense therapy in humans: namely, consistent down-regulation of the target protein in tumors excised from patients treated systemically with Genasense(TM).''
``The senior management at Genta has enormous depth in oncology drug development, having pulled numerous products through the NDA process at other companies. Our senior sales and marketing personnel have broad experience in the launch and management of blockbuster products in this sector. Our senior clinicians are internationally prominent in their fields, and they retain deep connections with the opinion leaders in hematology and oncology. This depth of experience, combined with our technical expertise, provides us with a tremendous competitive advantage over other companies in this space.''
In response to a question regarding Genta's patent position on Genasense(TM) and any implications of a patent regarding RNAse H, Dr. Warrell noted: ``Genta's holds a solid patent position on Genasense(TM), which we believe does not infringe the valid claims of any other patents. Furthermore, due to the extensive prior art, the commissioner of the U.S. Patent Office ordered re-examination of the RNAse H patent in question last July. We believe that publicly available information indicates that all claims even remotely affecting Genasense(TM) were rejected and withdrawn some time ago. Lastly, Genta itself holds a considerable patent position in antisense, and we intend to aggressively assert our rights with other companies that practice this technology.''
The audio feed of this presentation can be retrieved at: http://www.informedinvestors.com/iif_forums/event.cfm?forumID=194
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on anticancer therapy. The research platform is anchored by oligonucleotide chemistry, particularly applications of antisense technology. Genasense(TM), the Company's lead compound, has received ``Fast Track'' and ``Orphan Drug'' designation from the Food and Drug Administration. Genasense(TM) is currently undergoing late-stage, Phase 3 clinical testing. Genta's pipeline also comprises a portfolio of small molecules, including gallium-containing compounds for treatment of diseases associated with accelerated bone loss, Androgenics compounds for prostate cancer, and Decoy Aptamers for broad anticancer use. Genta aims to become a direct marketer of its pharmaceutical products in the United States. For more information about Genta, please visit our website at: http://www.genta.com.
The statements contained in this press release that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the expectations, beliefs, intentions or strategies regarding the future. Without limiting the foregoing, the words ``anticipates,'' ``believes,'' ``expects,'' ``intends,'' ``may'' and ``plans'' and similar expressions are intended to identify forward-looking statements. The Company intends that all forward-looking statements be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company's views as of the date they are made with respect to future events, but are subject to many risks and uncertainties, which could cause the actual results of the Company to differ materially from any future results expressed or implied by such forward- looking statements. For example, the results obtained in pre-clinical or clinical studies may not be indicative of results that will be obtained in future clinical trials, and delays in the initiation or completion of clinical trials may occur as a result of many factors. Further examples of such risks and uncertainties also include, but are not limited to: the obtaining of sufficient financing to maintain the Company's planned operations; timely development, receipt of necessary regulatory approvals, and acceptance of new products; the successful application of the Company's technology to produce new products; the obtaining of proprietary protection for any such technology and products; the impact of competitive products and pricing and reimbursement policies; and changing market conditions. The Company does not undertake to update forward- looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurances that the Company's expectations are correct. All forward looking statements are expressly qualified in their entirety by this cautionary statement and other factors detailed in the Company's reports filed with the Securities and Exchange Commission.
SOURCE: Genta Incorporated
New Management Report : )
By: eastcoaster10 $$$
Reply To: None Wednesday, 27 Jun 2001 at 10:57 AM EDT
Post # of 2892
Here's the latest Management Report that was just posted on the Juina website:
Management Report Update June 27, 2001
New Hirings
Management is committing to the development of the site by placing a new hire on the books of the Joint Venture. In anticipation of imminent issuance of all final licenses, the committee has procured the services of Jonathan Taylor, an able ore processor with experience in Angola. He has been hired as assistant to the Project Manager, Mousseau Tremblay and the Plant Manager Ron Turner. Management has considered the hiring of Mr. Taylor to be a priority and, given his fluency in English and Portuguese, expects he will be an enormous asset to the plant when production starts.
Plant Rehabilitation and Licensing
Procurement of the heavy equipment under appropriate terms is proceeding as planned. Management anticipates the heavy equipment will be on site in good time for issuance of licenses. FEMA-issued licenses are still in the hands of IBAMA and progress has been hampered by state and national holidays and the absence of appropriate authorized signatories. Confirmation that the paperwork is in the pipeline has been ascertained by our on-site geologist and we have assurances from the federal authority, the DNPM, that once they receive the paperwork from IBAMA that they will act with all haste to finalize our permissions. Management and shareholders are experiencing the same frustrations that come with delays and beaucracy when dealing with government institutions. Management is pleased to report that the Joint Venture is following all of the proper legal channels necessary to ensure that the property and the mine are in full compliance.
Mineral Sampling Program
Chief geologist, Dr. Mark Hutchison, has prepared his final report on heavy mineral sampling of alluvials and overburden of the 4.1 site on the 1000 Property. This site has been historically considered to be associated with a kimberlite-like magnetic anomaly and good diamond occurrence. It is intended that this location will be the first to be investigated on commencement of production. The principal findings have been an abundance of ilmenite of which an estimated 20% are picro-ilmenites of compositions expected in kimberlites and a further 5% also have high chromium contents (Cr2O3 up to 7.2% wt.). These ilmenites are comparable in composition to some of the most chromium-rich ilmenites associated with kimberlite and their discovery is considered to be very encouraging with regard to the kimberlite prospectivity of the Property.
Future news and updates will be forthcoming.
Forward-looking statements in this report are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties and actual results could differ from those discussed. This material is informational only and is not an offer or solicitation to buy or sell securities.
eVWAP 572,500 X 2
572,500x2
by: the_grand_poobah2000 06/27/01 09:51 am
Msg: 122041 of 122042
<EOM>
http://messages.yahoo.com/bbs?.mm=FN&action=m&board=4687979&tid=astn&sid=4687979&...
An example of a real scam... BOYI
Article from the Edmonton Journal (www.edmontonjournal.com - search on Boyle)
Brothers in contempt for 'evasive' testimony
Investors' lawsuit cites $1.5M in losses
Paul Marck, Journal Business Writer
The Edmonton Journal
In an unusual move, a Court of Queen's Bench justice has ordered two brothers from Vancouver jailed 10 days each for contempt.
Madame Justice Joanne Veit made the ruling Friday against Kevin Boyle, 34, and Jason Boyle, 26, both formerly of Edmonton.
The Boyles, along with brother Brian, 31, are the subject of civil proceedings that have carried on for two years after investors allegedly lost a total of $1.5 million they had placed with the Boyles and their associated companies.
In her ruling, Veit found the Boyles guilty of contempt at several points during the trial.
The jail term was handed down in connection with case proceedings from Sept. 30, 1999. Veit has also given Kevin and Jason Boyle a deadline of June 30 to purge their contempt from two related matters.
In the ruling, Veit said the Boyles were being sentenced to jail "for failing to have given meaningful answer to questions put to them on examination. ..."
In fact, she wrote: "There is not much tangible evidence that the Boyles have in fact made serious efforts to provide meaningful answers." Instead, the Boyles' responses were "evasive, incomplete and obstructionist."
Evidence at the lengthy trial showed that on many occasions, Kevin and Jason Boyle failed to provide details of their personal and corporate finances, despite being given ample time and opportunity to obtain records and information.
"However, by effectively stonewalling the investors, by maintaining they are unable to provide any information from Boyle International ... or how they could afford to pay lawyers hundreds of thousands of dollars, they have essentially denied to the investors even a shred of useful information," the ruling said.
Veit said it would not be useful to fine the Boyles any amount because proceeds would be paid to the court and not investors.
However, it's unlikely that either Kevin or Jason Boyle will be arrested and returned from their Vancouver homes to serve their jail time.
Instead, they'll likely be handcuffed once they return to court in Edmonton. Veit said in her ruling that she will take further action on the other contempt charges July 13, unless the Boyles purge those counts by June 30.
At one point, the Boyles agreed to an arrangement with the court to pay back investors a total of $900,000 over five years. The monthly payments, totalling $17,000 to several investors, stopped earlier this year.
The Boyles are also subject to separate proceedings for alleged violations of the Alberta Securities Act in connection with investments made in their companies.
Lawyer Karl Wilberg, who acted for the brothers on the contempt charge and for Kevin Boyle in the securities proceedings, declined comment.
GNTA and retail traders
by: cdmohaf (36/M/Cheyenne WY)
Long-Term Sentiment: Buy 06/25/01 08:05 pm
Msg: 28097 of 28170
There is some good discussion on this board, while I don't post much, I do lurk and listen. Both sides of the stories and points of view have good points. Let me throw another one at you. When you sell the stock, do you ever feel like your being baited? Watch your level II's and see who is at the bottom catching all of the shares we have been "trading". 9 million shares were accumulated, at a base of 10.5 to 11 and change. Do you think the people that are doing that, are looking for .5 point or a 1 point move. Not. Find another Biotech out there that is speculative, that has had the institutional buying that Genta has. ISIP's has actually decreased.
The lack of volume has been the INST allowing retail traders to sell into their bids, (buyers strike, but not selling for them), and they really don't care if we shave a dime or a quarter or a buck or whatever. One of these days that little trick isn't going to work. Some will be lucky, and will be in when they come in and buy their next position, based on data, that could be the Phase III or the CLL trials.
Look at the IMCL chart. When it moved in early 00 it did the exact same thing. It moved up, sold off, tried to convince people to shed shares, then shot up. Its a process and your dealing with people you can't beat. They handle your trades, so they know what you are doing, but you dont' know what htey are doing. Many MM's use Alias MM's to hide accumulation, and to hide shorting and selling. They slip the bids to catch anyone with a stop loss low or a cover limit high. The "trading" you talk about is allowed while they await economic, and trial data, as well as fed news. When they get the pieces in place, many a 'trader" will be frustrated, as he will be out of position when they come in and buy, or maybe sell.
It all comes down to a matter of the company, if you believe in the compnay and the INST's believe, then it will move up, but beware....the houses don't make this kind of committment just to walk away..with a small gain. If you think it looks bleak, and it looks bad, and the volume is low, it may be a worm on a hook with a MM holding the pole. Just ask the last group that sold under 11. If you could get the retail trade to hold firm, you would see them jump in sooner to take us higher, until then they will continue, to wait at the bottom on the bid, absorbing what little bit, they get. When they have absorbed enough...many of the "traders" will be left buying much higer....establishing a firm base well above their buyin price.
Watch the On Balance Volume, and Money Flow, I wont' bore you with all the signs, but anyone who cannot match that up with Level II and come up with what is going on.......
Just a thought from a guy who believes in Genta and I have a long position. I have watched this stock and tracked each movement for a long time.
Don't be caught otu of the ballgame or short. Your 100 dollar trades may seem like a gold mine now...but if your unlucky, and out of the stock when the MM's decide they have enough....then you will wish you had done things differently..
Good luck to all, I wish you well...
Dean
http://messages.yahoo.com/bbs?.mm=FN&action=m&board=7076854&tid=gnta&sid=7076854&...